Carboplatin

Carboplatin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Non-small Cell Lung Cancer With MTAP Deletion、Non-small Cell Lung Cancer、Carcinoma, Non-Small-Cell Lung、Advanced Endometrial Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Carboplatin 研究

• Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC

  II 期招募中中国NCT05941338

• Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  II 期招募中美国NCT02605421

• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

  II 期招募中中国NCT06497530

• Pathological Response After Neoadjuvant Treatment on NSCLC

  不适用招募中西班牙NCT05167487

• Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

  III 期招募中中国NCT06008106

• Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

  不适用招募中中国NCT05595408

• Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

  II 期招募中中国NCT04807140

• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

  II 期招募中美国NCT07743190

• Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

  II 期招募中中国NCT06467617

• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

  II 期招募中美国NCT06245889

• Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

  早期 I 期招募中美国NCT05553782

• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  II 期招募中美国NCT06745882

• Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

  II 期招募中美国NCT04992780

• A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

  I 期 / II 期招募中中国NCT06840002

• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  I 期 / II 期招募中美国中国法国德国NCT06385080

• Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  III 期招募中法国NCT04747054

• A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  III 期招募中美国ArgentinaChile中国NCT07022483

• A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

  I 期 / II 期招募中中国NCT06682780

• A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

  II 期招募中中国NCT07108270

• AB122 Platform Study

  I 期招募中日本NCT04999761

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  II 期招募中美国NCT01042379

• A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

  II 期招募中中国NCT07082179

• JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

  III 期招募中中国NCT06416410

• Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

  II 期招募中中国NCT07492342

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。